Total Economic Burden (2023)
$107.2B
Across 14 countries · Psoriasis + Atopic Dermatitis
People Affected (2023)
147.3M
Prevalence, both conditions
Avg. Burden per Person
$728
Total burden ÷ people affected
Combined NIH Research Funding
$3.29B
Psoriasis + Atopic Dermatitis, all years
Skin Economic Burden Index (SEBI) 2023
Top 5 Countries by SEBI Score
- 1PhilippinesMedium72.1
- 2ChinaMedium62.9
- 3United Arab EmiratesMedium59.3
- 4GermanyHigh59.0
- 5BrazilMedium57.9
SEBI Components (Global Average)
- Healthcare Costs40.0%
- Employment Penalty33.3%
- Productivity Loss26.7%
- Psychological BurdenData Not Available
Trends Over Time (Global)
Country Comparison
Disease Profile Snapshot
Psoriasis
A chronic immune-mediated condition producing raised, scaly plaques on the skin. It is not contagious, though its visibility frequently prompts others to assume otherwise.
- People Affected (2023)
- 17.81M
- Economic Burden (2023)
- $33.23B
- NIH Research Funding
- $1.68B
At a Glance
Highest Burden Region
East Asia & Pacific (avg SEBI 62.1)
Most Affected Age Group
Data not availableThe dataset has no age breakdown, so this cannot be reported.
Gender Disparity (Employment Penalty)
Male: 14.2% · Female: 2.9%
Average across 6 countries with disability-earnings data.
Most Underfunded Disease
Vitiligo ($205.4M NIH)
Current Research Gaps
Limited Mental Health Data
No standardised, country-level data on psychological distress exists. This is why the Psychological Burden component is excluded from SEBI rather than estimated.
Underreported Indirect Costs
Presenteeism, caregiver burden and long-term productivity losses are not captured in the sources used for this phase.
Informal Economy Impact
ILOSTAT informal employment data has not been incorporated in this phase, so employment and income losses in the informal sector are not measured.
Funding Transparency
NIH RePORTER is the only funding data source available. It is US-only and reported globally per disease rather than per country, so no country-level funding comparison is possible.